VIENNA, Va., Oct. 17 /PRNewswire-FirstCall/ -- CEL-SCI CORPORATION , a drug development company with its lead cancer product cleared for a Phase III trial, announces that it will hold its annual meeting on Friday, November 17, 2006 at 12 PM at the Steigenberger Frankfurter Hof, Am Kaiserplatz, 60311 in Frankfurt am Main, Germany.
Maximilian de Clara, President of CEL-SCI Corporation said, "In addition to our U.S. listing, our stock is actively traded on five German stock exchanges where we also have many investors. We would like to give these investors the chance to meet with management and we feel that holding the meeting in Germany is a good way of achieving this goal."
Shareholders and investors who plan to attend the meeting are asked to let the Company know either by e-mail at cel-sci@cel-sci.com or by fax at U.S. (703) 506-9471.
CEL-SCI Corporation is developing new immune system based treatments for cancer and infectious diseases. The Company has operations in Vienna, Virginia and Baltimore, Maryland. The Company's lead product Multikine(R) is cleared to enter global Phase III clinical trials in advanced primary head and neck cancer patients. CEL-SCI's other products, which are currently in pre- clinical stage and are funded with U.S. government support, have shown protection against a number of diseases in animal tests and are being tested against diseases associated with bio-defense and avian flu.
CEL-SCI CorporationCONTACT: Gavin de Windt of CEL-SCI Corporation, +1-703-506-9460, Fax:+1-703-506-9471
Web site: http://www.cel-sci.com//
